ARS Pharmaceuticals (SPRY) Insider Shawver Buys 30,000 Shares
Laura Shawver bought 30,000 shares of ARS Pharmaceuticals at $8.54 each on June 24, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Laura Shawver bought 30,000 shares of ARS Pharmaceuticals, Inc. ($SPRY) on June 24, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $SPRY is down 24.7% after 1 week, down 43.6% after 1 month and down 61.9% to date (from the $10.54 close on Jun 24, 2026).
SPRY
ARS Pharmaceuticals, Inc.
Key Points
- On June 24, 2026, Laura Shawver bought 30,000 shares of ARS Pharmaceuticals, Inc. (NasdaqGM: SPRY) at $8.54 each.
- ARS Pharmaceuticals has seen a recent share price range between $4.07 and $13.15, closing at $4.11 prior to this purchase.
- Analysts have a consensus rating of 'strong buy' for ARS Pharmaceuticals, with a mean price target of $22.50.
Get $SPRY trade alerts by text
We text you when insiders, Congress or big funds trade $SPRY. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated ARS Pharmaceuticals, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at ARS Pharmaceuticals, Inc.
Laura Shawver purchased 30,000 shares of ARS Pharmaceuticals, Inc. (NasdaqGM: SPRY) on June 24, 2026, at a price of $8.54 per share. This transaction reflects a growing confidence among insiders in the company's future prospects, as several other executives made similar purchases on the same day.
Other Insiders Join the Buying Trend
On the same day, five other insiders also bought 30,000 shares each of ARS Pharmaceuticals. Phillip Schneider, Pratik Shah, Saqib Islam, Brent Saunders, and Peter Thompson all made identical transactions, signaling a collective belief in the company's potential. Each insider's purchase occurred at the same price of $8.54, aligning their interests with the future success of ARS Pharmaceuticals.
Stock Performance Context
ARS Pharmaceuticals' stock has fluctuated between $4.07 and $13.15 over the past year. The share price closed at $4.11 before the recent insider purchases, indicating that the stock trades well below its 52-week high. This current price point suggests potential upside as the company continues to develop its innovative treatments for severe allergic reactions.
Analysts Set New Price Targets
On June 25, 2026, Leerink Partners maintained an 'Outperform' rating for ARS Pharmaceuticals, adjusting their price target from $25.00 to $24.00. They reaffirmed their 'Outperform' rating again on August 13, 2026, with a new target of $18.00. The consensus among analysts is a strong buy, with a mean price target of $22.50 based on four analyst opinions.
What ARS Pharmaceuticals, Inc. Does
ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for severe allergic reactions. The company is known for its product neffy, a needle-free delivery system for epinephrine, designed for emergency treatment of anaphylaxis. The recent insider purchases could reflect confidence in the company's ongoing projects and market strategy.
What's Ahead for ARS Pharmaceuticals, Inc.
Investors will be watching ARS Pharmaceuticals closely, especially with the next earnings report scheduled for November 10, 2026. The recent insider transactions demonstrate a commitment to the company's direction, and it's important to note that these trades reflect past decisions and may not represent current holdings.
Related Filing Alerts
Source: Laura Shawver's Form 4 filing on $SPRY (Jun 24, 2026). Find the original filing: SPRY Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts